<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="pmc-domain-id">2786</journal-id><journal-id journal-id-type="pmc-domain">medicine</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431739</article-id><article-id pub-id-type="pmcid-ver">PMC12431739.1</article-id><article-id pub-id-type="pmcaid">12431739</article-id><article-id pub-id-type="pmcaiid">12431739</article-id><article-id pub-id-type="pmid">39252331</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000039475</article-id><article-id pub-id-type="publisher-id">MD-D-24-03119</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>4800</subject></subj-group><subj-group><subject>Research Article</subject><subject>Systematic Review and Meta-Analysis</subject></subj-group></article-categories><title-group><article-title>The role of prophylactic transfusion on the maternal and fetal outcomes in pregnant women with sickle cell disease: A systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-7400-3904</contrib-id><name name-style="western"><surname>AlMoshary</surname><given-names initials="M">May</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arabdin</surname><given-names initials="M">Maria</given-names></name><degrees>MBBS, MPhil</degrees><email>maria-arabdin@outlook.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><aff id="aff1"><label>a</label>Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia</aff><aff id="aff2"><label>b</label>Qazi Hussain Ahmad Medical Complex, Nowshera Medical College, Nowshera, Khyber Pakhtunkhwa , Pakistan.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: May AlMoshary, Basic Science Department, College of Medicine, Princess Nourah bint Abdulrahman University, Box 84428, Riyadh 11671, Saudi Arabia (e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Hemmai2020@yahoo.com">Hemmai2020@yahoo.com</email>).</corresp></author-notes><pub-date pub-type="collection"><day>06</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>06</day><month>9</month><year>2024</year></pub-date><volume>103</volume><issue>36</issue><issue-id pub-id-type="pmc-issue-id">470382</issue-id><elocation-id>e39475</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2024</year></date><date date-type="received"><day>10</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>07</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medi-103-e39475.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medi-103-e39475.pdf"/><abstract><sec><title>Background:</title><p>In the present review, we aimed to synthesize evidence from studies on the safety and effectiveness of prophylactic blood transfusion in pregnant women with sickle cell disease.</p></sec><sec><title>Material and methods:</title><p>To gather relevant information, we conducted systematic electronic searches of databases such as SCOPUS, Medline via PubMed, Web of Science, and Cochrane Central Register of Controlled Trials. We included both retrospective and prospective studies that examined the impact of prophylactic blood transfusions during pregnancy. The collected data were analyzed using Review Manager, version 5.3.</p></sec><sec><title>Results:</title><p>The review included 15 cohort studies. The overall findings indicated a preference for the prophylactic blood transfusion group over the control group across several key parameters. Specifically, the prophylactic group demonstrated lower rates of maternal mortality (odds ratio [OR]&#8197;=&#8197;0.33; 95% confidence interval [CI] = 0.10&#8211;1.13; <italic toggle="yes">P</italic>&#8197;=&#8197;.08), reduced incidence of vaso-occlusive painful events (OR&#8197;=&#8197;0.31; 95% CI = 0.14&#8211;0.73; <italic toggle="yes">P</italic>&#8197;=&#8197;.007), fewer pulmonary complications (OR&#8197;=&#8197;0.21; 95% CI = 0.08&#8211;0.53; <italic toggle="yes">P</italic>&#8197;=&#8197;.001), decreased perinatal mortality (OR&#8197;=&#8197;0.35; 95% CI = 0.17&#8211;0.75; <italic toggle="yes">P</italic>&#8197;=&#8197;.03), and lower likelihood of preterm birth (OR&#8197;=&#8197;0.67; 95% CI = 0.47&#8211;0.96; <italic toggle="yes">P</italic>&#8197;=&#8197;.02). Notably, statistically significant heterogeneities were observed in the pooled effect estimates.</p></sec><sec><title>Conclusion:</title><p>The present meta-analysis indicated that prophylactic blood transfusion in pregnant women with sickle cell disease may improve maternal and fetal outcomes. However, substantial variations in the methodology and transfusion protocols among the included studies limited the credibility of the current evidence supporting the routine clinical use of prophylactic transfusion for SCD during pregnancy.</p></sec></abstract><kwd-group><kwd>blood transfusion</kwd><kwd>meta-analysis</kwd><kwd>sickle cell disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Sickle cell disease (SCD) is one of the most commonly inherited disorders globally and is characterized by diverse clinical severities and potential serious complications.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> The progression and severity of the disease primarily hinge on the SCD genotype, with hemoglobin (HbS) SS and HbS/&#946;0 exhibiting greater severity, whereas HbSC and HbS/&#946;+ manifested a milder course; however, adverse events have been noted across all subtypes.<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup></p><p>A sickle point mutation in the <italic toggle="yes">&#946;-globin</italic> gene leads to the production of abnormal sickle-shaped erythrocytes containing sickle HbS, which has lower solubility than normal fetal or adult HbS and is prone to polymerization in the absence of oxygen.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> These resulting polymers reduce the deformability of erythrocytes and disrupt blood flow in small vessels. This, along with changes in the red blood cell volume and enhanced attachment to the vascular endothelium, initiates inflammation and the pathophysiological mechanisms of blood vessel blockage and red blood cell breakdown.<sup>[<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>]</sup> These occurrences are especially evident in hypoxic situations, resulting in damage from ischemia-reperfusion, endothelial dysfunction, and damage to multiple organs.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup></p><p>Pregnant women with SCD face significant risk, as evidenced by multiple reports highlighting elevated rates of maternal morbidity and mortality, as well as adverse perinatal outcomes such as vaso-occlusive pain episodes, pulmonary complications, preeclampsia, low-birth-weight infants, preterm birth, maternal mortality, and perinatal mortality.<sup>[<xref rid="R5" ref-type="bibr">5</xref>&#8211;<xref rid="R9" ref-type="bibr">9</xref>]</sup> A recent systematic review and meta-analysis by Oteng-Ntim et al<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> further quantified these risks, indicating that women with SCD are at a heightened risk of experiencing preeclampsia, maternal death, stillbirths, preterm deliveries, and small-for-gestational-age (SGA) newborns.</p><p>Prophylactic blood transfusion has been proposed as a strategy to mitigate complications associated with SCD by addressing severe anemia, reducing sickling in both maternal and placental circulation, and improving blood flow and oxygenation.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> The beneficial effects of transfusion in SCD have been substantiated in various contexts, including preoperative optimization and prophylaxis against stroke.<sup>[<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>]</sup> However, the role of prophylactic transfusions in SCD during pregnancy has been debated. A previous Cochrane systematic review highlighted the lack of clear evidence regarding the efficacy of prophylactic transfusion in SCD pregnancies, leading to the withdrawal of the corresponding article.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> Subsequent individual studies have reported conflicting results regarding elective blood transfusion as a prophylactic measure in reducing painful crises, preventing acute chest syndrome, and managing other complications associated with SCD.<sup>[<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref>]</sup></p><p>A recent meta-analysis conducted by Malinowski et al<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> showed a correlation between prophylactic blood transfusion in pregnant women with SCD and a reduction in maternal mortality, episodes of vaso-occlusive pain, and pulmonary complications. However, the authors noted that the relatively small number of included studies and their methodological limitations prevented them from making definitive statements regarding the role of prophylactic blood transfusion in SCD pregnancies.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> As a result, our study aimed to systematically review both the latest updates and previous studies to assess the impact of prophylactic transfusion compared with on-demand transfusion on maternal and fetal outcomes in pregnant women with SCD.</p></sec><sec sec-type="methods"><title>2. Materials and methods</title><p>This systematic review and meta-analysis was conducted following the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis and Meta-Analysis of Observational Studies in Epidemiology statements.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup></p><sec><title>2.1. Inclusion and exclusion criteria</title><p>This review incorporated both prospective and retrospective studies that met the following criteria: (1) studies involving pregnant women with SCD; (2) studies evaluating the safety and effectiveness of routine prophylactic blood transfusion in pregnant women with SCD; and (3) In studies comparing prophylactic transfusion with an on-demand transfusion approach, we prioritized the most comprehensive report when multiple reports were available. We excluded non-English studies, reviews, theses, and conference proceedings.</p></sec><sec><title>2.2. Search strategy and screening</title><p>An electronic search was conducted from the beginning of available records until January 2024 in multiple bibliographic databases, including Medline via PubMed, Web of Science, SCOPUS, and the Cochrane Central Register of Controlled Trials. Different combinations of keywords, such as &#8220;prophylactic transfusion,&#8221; &#8220;pregnancy,&#8221; &#8220;sickle-cell disease,&#8221; and &#8220;SCD,&#8221; were utilized during the search procedure. The identified citations were imported into EndNote 21 to eliminate any duplicates. Afterward, the unique citations were transferred to an Excel spreadsheet and independently evaluated by 2 reviewers. The evaluation process consisted of 2 stages: an initial assessment based on titles and abstracts followed by a comprehensive review of full texts to identify potentially eligible records.</p></sec><sec><title>2.3. Data extraction and efficacy measures</title><p>Data entry and processing were performed using an Excel spreadsheet, where 2 reviewers were tasked with extracting information from the studies included in the analysis. The extracted information covered several areas, including (1) demographic and methodological characteristics of the studies, (2) assessment of bias in the studied populations, (3) specifics of transfusion protocols, and (4) study outcomes. Both reviewers independently gathered data from the included articles and resolved any discrepancies through discussion. The outcomes assessed in studies examining the prophylactic transfusion&#8217;s impact on SCD during pregnancy included maternal mortality, perinatal mortality, occurrences of vaso-occlusive painful events, preeclampsia, pulmonary complications, preterm birth, and SGA babies.</p></sec><sec><title>2.4. Risk-of-bias assessment</title><p>The evaluation of the retrieved observational studies&#8217; quality utilized the Newcastle Ottawa Scale. This assessment considered the selection of study groups, comparability between groups, and the ascertainment of exposure or outcome. Each study was assigned a cumulative quality score ranging from 1 to 9, and based on this score, studies were classified into categories of high risk of bias (scores 1&#8211;3), moderate risk of bias (scores 4&#8211;6), and low risk of bias (scores 7&#8211;9).<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup></p></sec><sec><title>2.5. Data synthesis</title><p>We performed a paired comparison meta-analysis utilizing the Review Manager, version 5.3, software designed for Windows. The combination of dichotomous data was done as odds ratios (ORs) accompanied by 95% confidence intervals (CIs) employing the Mantel-Haenszel method. The heterogeneity of the combined effect estimates was evaluated using the I<sup>2</sup> statistic alongside its respective <italic toggle="yes">P</italic> values. Due to significant heterogeneity among the studies included, we opted for a random-effects model. All reported <italic toggle="yes">P</italic> values were 2 sided, and statistical significance was considered for <italic toggle="yes">P</italic> values &lt; .05.</p></sec></sec><sec sec-type="results"><title>3. Results</title><sec sec-type="results"><title>3.1. Literature search results</title><p>The initial literature search resulted in 1459 unique citations after removing duplicates. After title and abstract screening, 45 potentially eligible records were identified for full evaluation. Ultimately, 15 studies were included in this systematic review and meta-analysis (931 patients in the prophylactic group and 854 patients in the control group) (Fig. <xref rid="F1" ref-type="fig">1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Screening and selection of included studies by PRISMA guidelines. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39475-g001.jpg"/></fig></sec><sec><title>3.2. Characteristics of studies</title><p>The present review comprised 15 quasi-randomized trials.<sup>[<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R20" ref-type="bibr">20</xref>&#8211;<xref rid="R31" ref-type="bibr">31</xref>]</sup> All quasi-trials were retrospective cohort studies, except for the study by Morrison et al,<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> which was a prospective cohort study with a historical control group. The sample sizes of the included studies ranged from 24 to 571 patients. Notably, there were significant variations in the protocols for prophylactic blood transfusion for SCD among the included studies. Additionally, studies have reported conflicting results regarding the efficacy and safety of prophylactic blood transfusion for SCD. Tables <xref rid="T1" ref-type="table">1</xref> and <xref rid="T2" ref-type="table">2</xref> provide detailed characteristics of the included studies.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of studies included.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="8" rowspan="1">Cohort studies</th></tr><tr><th align="center" rowspan="1" colspan="1">Author, year</th><th align="center" rowspan="1" colspan="1">Country setting</th><th align="center" rowspan="1" colspan="1">Single versus multicenter</th><th align="center" rowspan="1" colspan="1">Groups</th><th align="center" rowspan="1" colspan="1">Sample size</th><th align="center" rowspan="1" colspan="1">Years of study</th><th align="center" rowspan="1" colspan="1">Inclusion criteria</th><th align="center" rowspan="1" colspan="1">Conclusion</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Benites et al, 2016<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup></td><td align="left" rowspan="2" colspan="1">The University of Campinas Hospital</td><td align="left" rowspan="2" colspan="1">Single-center retrospective cohort</td><td align="left" rowspan="1" colspan="1">Administering either prophylactic erythrocytapheresis or manual exchange transfusion during the 28th week of pregnancy</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="2" colspan="1">June 1994 and August 2014</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">The research showed a significant decrease in negative outcomes among patients who received preventive transfusions, likely indicating improved maternal and fetal health conditions. This also aligned with the better vitality indicators observed in newborns.</td></tr><tr><td align="left" rowspan="1" colspan="1">Transfusions are given only when necessary due to acute complications, or in some cases, no transfusions are required at all</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="2" colspan="1">Asma et al, 2015<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup></td><td align="left" rowspan="2" colspan="1">Turkey</td><td align="left" rowspan="2" colspan="1">Single-center retrospective cohort</td><td align="left" rowspan="1" colspan="1">Prophylactic blood transfusion</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="2" colspan="1">2000&#8211;2013</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">This study has shown that administering pRBCX during pregnancy is a viable and safe approach to prevent complications.</td></tr><tr><td align="left" rowspan="1" colspan="1">Indicated transfusion</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="2" colspan="1">Gilli et al, 2007<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup></td><td align="left" rowspan="2" colspan="1">Brazil</td><td align="left" rowspan="2" colspan="1">Single-center retrospective cohort</td><td align="left" rowspan="1" colspan="1">Administering prophylactic erythrocytapheresis transfusions at the start of the third trimester</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="2" colspan="1">1994&#8211;2004</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">The research indicates that erythrocytapheresis transfusions offer advantages for women with SCD in the 3rd trimester.</td></tr><tr><td align="left" rowspan="1" colspan="1">Providing basic preventive transfusions solely based on the severity of SCD, without any other specific indication</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="2" colspan="1">Howard et al, 1995<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup></td><td align="left" rowspan="2" colspan="1">United Kingdom Hospitals in England and Wales</td><td align="left" rowspan="2" colspan="1">Multicenter retrospective cohort</td><td align="left" rowspan="1" colspan="1">Prophylactic blood transfusion</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="2" colspan="1">1991&#8211;1993</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">It is advised to implement a strategy of exchanging transfusions for all women with homozygous SCD (HbSS) starting from the 28th week of pregnancy to minimize the chances of maternal complications during the third trimester and postpartum period.</td></tr><tr><td align="left" rowspan="1" colspan="1">Indicated transfusion</td><td align="center" rowspan="1" colspan="1">34</td></tr><tr><td align="left" rowspan="2" colspan="1">El-Shafei et al, 1995<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup></td><td align="left" rowspan="2" colspan="1">Bahrain Ministry of Health Hospitals</td><td align="left" rowspan="2" colspan="1">Single-center mixed retrospective and prospective cohorts</td><td align="left" rowspan="1" colspan="1">Prophylactic blood transfusion</td><td align="center" rowspan="1" colspan="1">244</td><td align="center" rowspan="2" colspan="1">Prospective: 1988&#8211;1994<break/>Retrospective: 1986&#8211;1988</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">A cautious approach to blood transfusion can be implemented without putting at risk the health of the fetus or mother, and it also offers the added advantage of decreasing the occurrence of transfusion-related crises and other associated complications.</td></tr><tr><td align="left" rowspan="1" colspan="1">Indicated transfusion</td><td align="center" rowspan="1" colspan="1">327</td></tr><tr><td align="left" rowspan="2" colspan="1">Koshy et al, 1991<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup></td><td align="left" rowspan="2" colspan="1">United States</td><td align="left" rowspan="2" colspan="1">Single-center retrospective cohort</td><td align="left" rowspan="1" colspan="1">Prophylactic transfusion, beginning at the early weeks of pregnancy</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="2" colspan="1">1986&#8211;1990</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Transfusion only</td><td align="center" rowspan="1" colspan="1">35</td></tr><tr><td align="left" rowspan="2" colspan="1">Morrison et al, 1991<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup></td><td align="left" rowspan="2" colspan="1">United States</td><td align="left" rowspan="2" colspan="1">Single-center retrospective cohort with controls</td><td align="left" rowspan="1" colspan="1">Performing a partial prophylactic exchange transfusion early in prenatal care</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">January 1981 to December 1990</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">The findings suggest an advantage of using this approach in treating pregnant patients with SCD.</td></tr><tr><td align="left" rowspan="1" colspan="1">Indicated transfusion on demand</td><td align="center" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Tuck et al, 1987<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup></td><td align="left" rowspan="2" colspan="1">United Kingdom</td><td align="left" rowspan="2" colspan="1">Multicenter retrospective cohort</td><td align="left" rowspan="1" colspan="1">Prophylactic blood transfusion</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="2" colspan="1">1978&#8211;1984 (prophylactic transfusion)<break/>1975&#8211;1981 (untransfused)</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">The data show no significant difference in fetal or maternal outcome between those patients who were transfused prophylactically and those who were not.</td></tr><tr><td align="left" rowspan="1" colspan="1">Indicated transfusion</td><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="2" colspan="1">Cunningham et al, 1983<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup></td><td align="left" rowspan="2" colspan="1">United States</td><td align="left" rowspan="2" colspan="1">Single-center retrospective cohort with historical controls</td><td align="left" rowspan="1" colspan="1">Prophylactic blood transfusion</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="2" colspan="1">1973&#8211;1982 (PT)<break/>1955&#8211;1972 (ODT)</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">Prophylactic blood transfusions significantly decrease maternal complications and the risk of perinatal death.</td></tr><tr><td align="left" rowspan="1" colspan="1">Indicated transfusion</td><td align="center" rowspan="1" colspan="1">54</td></tr><tr><td align="left" rowspan="2" colspan="1">Miller et al, 1981<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup></td><td align="left" rowspan="2" colspan="1">United States</td><td align="left" rowspan="2" colspan="1">Single-center retrospective cohort with controls</td><td align="left" rowspan="1" colspan="1">Prophylactic blood transfusion</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="2" colspan="1">1978&#8211;1980 (prophylactic transfusion)<break/>1974&#8211;1979 (on-demand transfusion)<break/>Historical controls</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">The exchange transfusion may best be reserved as a treatment modality when infection, crises, or symptomatic anemia occurs in gravidae with sickle hemoglobinopathies.</td></tr><tr><td align="left" rowspan="1" colspan="1">Indicated transfusion</td><td align="center" rowspan="1" colspan="1">36</td></tr><tr><td align="left" rowspan="2" colspan="1">Morrison et al, 1976<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup></td><td align="left" rowspan="2" colspan="1">United States</td><td align="left" rowspan="2" colspan="1">Single-center prospective cohort, matched retrospectively with historical controls</td><td align="left" rowspan="1" colspan="1">Prophylactic blood transfusion</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="2" colspan="1">1970&#8211;1974<break/>1965&#8211;1970</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">Administering prophylactic partial exchange transfusions to pregnant individuals with severe sickle cell hemoglobinopathies can be advantageous.</td></tr><tr><td align="left" rowspan="1" colspan="1">Indicated transfusion</td><td align="center" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">Ribeil et al, 2018<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup></td><td align="left" rowspan="1" colspan="1">France</td><td align="left" rowspan="1" colspan="1">Multicenter retrospective cohort study</td><td align="left" rowspan="1" colspan="1">Prophylactic transfusion strategy</td><td align="center" rowspan="1" colspan="1">191 cases</td><td align="center" rowspan="1" colspan="1">- 2005&#8211;2010<break/>2011&#8211;2014</td><td align="center" rowspan="1" colspan="1">SCD</td><td align="left" rowspan="1" colspan="1">It is safe to combine targeted transfusion with preventive at-home nocturnal oxygen therapy to lower the need for transfusions and the risks associated with them.</td></tr><tr><td align="left" rowspan="2" colspan="1">Yilmaz Baran et al, 2020<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup></td><td align="left" rowspan="2" colspan="1">Turkey</td><td align="left" rowspan="2" colspan="1">Single-center, retrospective, cross-sectional study</td><td align="left" rowspan="2" colspan="1">pRBCX</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="2" colspan="1">January 2012 and June 2019</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">It shows that by reducing adverse fetomaternal outcomes, pRBCX in SCD positively impacts the course of pregnancy.</td></tr><tr><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="2" colspan="1">Ngo et al, 2010<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup></td><td align="left" rowspan="2" colspan="1">France</td><td align="left" rowspan="2" colspan="1">Retrospective case-control study</td><td align="left" rowspan="2" colspan="1">Prophylactic blood transfusion</td><td align="center" rowspan="1" colspan="1">SCD = 128</td><td align="center" rowspan="2" colspan="1">January 2019</td><td align="center" rowspan="2" colspan="1">SCD</td><td align="left" rowspan="2" colspan="1">The prevalence of SCD remains the same, and as severe complication, it affects pregnant women despite prophylactic blood transfusion.</td></tr><tr><td align="center" rowspan="1" colspan="1">AA phenotype = 128</td></tr><tr><td align="left" rowspan="1" colspan="1">Sousa et al, 2022<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup></td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Multicenter, retrospective, cross-sectional study</td><td align="left" rowspan="1" colspan="1">Prophylactic transfusions</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">January 1, 2010, to December 31, 2019</td><td align="center" rowspan="1" colspan="1">SCD</td><td align="left" rowspan="1" colspan="1">The current study&#8217;s findings regarding the decreased incidence of fetal death during pregnancy in women who received more transfusions during their pregnancies.</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>HbSS = hemoglobin SS, ODT = on demand transfusion, pRBCX = prophylactic red blood cell exchange, PT = prophylactic transfusion, SCD = sickle cell disease.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Summary of management and transfusion protocols.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="10" rowspan="1">Cohort studies</th></tr><tr><th align="center" rowspan="2" colspan="1">Author, year</th><th align="center" colspan="5" rowspan="1">Prophylactic transfusion</th><th align="center" colspan="4" rowspan="1">On-demand transfusion</th></tr><tr><th align="center" rowspan="1" colspan="1">Type of transfusion</th><th align="center" rowspan="1" colspan="1">Timing of initiation, GA (wk)</th><th align="center" rowspan="1" colspan="1">MUT</th><th align="center" rowspan="1" colspan="1">Proportion requiring ODT (%)</th><th align="center" rowspan="1" colspan="1">Initial targets subsequent triggers</th><th align="center" rowspan="1" colspan="1">Reason for transfusion</th><th align="center" rowspan="1" colspan="1">Timing of initiation, GA (wk)</th><th align="center" rowspan="1" colspan="1">MUT</th><th align="center" rowspan="1" colspan="1">Proportion requiring ODT (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Asma et al, 2015<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Continuous-flow apheresis</td><td align="center" rowspan="1" colspan="1">Variable</td><td align="center" rowspan="1" colspan="1">6.2&#8197;&#177;&#8197;0.6</td><td align="center" rowspan="1" colspan="1">16.7%</td><td align="center" rowspan="1" colspan="1">Target: HbS &lt; 30%<break/>Trigger: Hb &lt; 7.0&#8201;mg/dL, Hct = 27%</td><td align="center" rowspan="1" colspan="1">Simple transfusion: Hb&#8197;&lt;&#8197;7.0&#8201;mg/dL, leukocytosis in the absence of infection</td><td align="center" rowspan="1" colspan="1">1st and 3rd trimesters</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">15%</td></tr><tr><td align="left" rowspan="1" colspan="1">Gilli et al, 2007<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Erythrocytapheresis</td><td align="center" rowspan="1" colspan="1">28th</td><td align="center" rowspan="1" colspan="1">8.14&#8197;&#177;&#8197;4.31</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: NA<break/>Trigger: NA</td><td align="center" rowspan="1" colspan="1">Acute complications of SCD</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">3.7&#8197;&#177;&#8197;2.7</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Howard et al, 1995<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Transfusion depending on the severity of anemia</td><td align="center" rowspan="1" colspan="1">1st or 3rd trimester</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: NA<break/>Trigger: NA</td><td align="center" rowspan="1" colspan="1">Complications of SCD</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">26%</td></tr><tr><td align="left" rowspan="1" colspan="1">El-Shafei et al, 1995<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Partial transfusion</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">60.7%</td><td align="center" rowspan="1" colspan="1">Target: NA<break/>Trigger: NA</td><td align="center" rowspan="1" colspan="1">Low Hb&#8197;&lt;&#8197;60&#8201;mg/dL, sickle crisis</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">29.4%</td></tr><tr><td align="left" rowspan="1" colspan="1">Koshy et al, 1991<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Simple or partial exchange transfusion</td><td align="center" rowspan="1" colspan="1">1st transfusion</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: HbS &lt; 35%<break/>Trigger: NA</td><td align="center" rowspan="1" colspan="1">Before C/S, severe anemia</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">74%</td></tr><tr><td align="left" rowspan="1" colspan="1">Morrison et al, 1991<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Partial exchange transfusion</td><td align="center" rowspan="1" colspan="1">19.4</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: HbA &gt; 50%<break/>Trigger: HbA&#8197;&lt;&#8197;20%</td><td align="center" rowspan="1" colspan="1">Severe anemia</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">58%</td></tr><tr><td align="left" rowspan="1" colspan="1">Tuck et al, 1987<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Simple or partial exchange transfusion</td><td align="center" rowspan="1" colspan="1">Depending on HbSS</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: Hb = 11.0&#8201;mg/dL<break/>Trigger: NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Cunningham et al, 1983<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Simple transfusion or partial exchange transfusion</td><td align="center" rowspan="1" colspan="1">20th week of gestation</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: HbA = 50%<break/>Trigger: HbA&#8197;&lt;&#8197;40%</td><td align="center" rowspan="1" colspan="1">Hb&#8197;&lt;&#8197;7.0&#8201;mg/dL</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Miller et al, 1981<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Partial exchange transfusion</td><td align="center" rowspan="1" colspan="1">23rd</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: NA<break/>Trigger: HbA&#8197;&lt;&#8197;25%</td><td align="center" rowspan="1" colspan="1">Hb&#8197;&lt;&#8197;7.0&#8201;mg/dL</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Morrison et al, 1976<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Partial exchange transfusion</td><td align="center" rowspan="1" colspan="1">28th</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">5.6%</td><td align="center" rowspan="1" colspan="1">Target: HbA = 40%<break/>Trigger: HbA&#8197;&lt;&#8197;20%</td><td align="center" rowspan="1" colspan="1">Severe anemia</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">38%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ribeil et al, 2018<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Simple transfusion</td><td align="center" rowspan="1" colspan="1">28th</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: HbA &#8805; 25%<break/>Trigger: Hct &#8804; 25%, HbA &#8804; 20%</td><td align="center" rowspan="1" colspan="1">Severe anemia</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Yilmaz Baran et al, 2020<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Partial exchange transfusion</td><td align="center" rowspan="1" colspan="1">3rd trimester</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: HbS &#8804; 30%<break/>Trigger: Hb &#8804; 9&#8201;mg/dL</td><td align="center" rowspan="1" colspan="1">Anemia, vaso-occlusion crisis</td><td align="center" rowspan="1" colspan="1">NR</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2%</td></tr><tr><td align="left" rowspan="1" colspan="1">Ngo et al, 2010<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Partial exchange transfusion</td><td align="center" rowspan="1" colspan="1">3rd trimester</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: Hb = 9&#8201;mg/dL, HbS &#8804; 40%<break/>Trigger: Hb &#8804; 9&#8201;mg/dL</td><td align="center" rowspan="1" colspan="1">Severe anemia, crisis</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">2.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Sousa et al, 2022<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup></td><td align="center" rowspan="1" colspan="1">Partial exchange transfusion</td><td align="center" rowspan="1" colspan="1">3rd trimester</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">Target: Hb = 10&#8201;g/dL, HbS &#8804; 50%<break/>Trigger: Hb = 8.0 mg/dL</td><td align="center" rowspan="1" colspan="1">Severe anemia, crisis</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">40.7%</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>C/S = cesarian section, GA = gestational age, Hb = hemoglobin, HbS = hemoglobin, HbSS = hemoglobin SS, Hct = hematocrit, MUT = mutation, NA = not available, NR = not reported, ODT = on demand transfusion, SCD = sickle cell disease, SHbA = adult hemoglobin.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>3.3. Risk-of-bias assessment</title><p>In the included studies, risk of bias ranged from moderate to high according to the Newcastle Ottawa Scale. Specifically, all studies exhibited a high risk of bias in the comparability and follow-up domains. A summary of the risk-of-bias assessment is provided in Table S1, Supplemental Digital Content, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/MD/N452" ext-link-type="uri">http://links.lww.com/MD/N452</ext-link>.</p></sec><sec><title>3.4. Outcomes</title><sec><title>3.4.1. Maternal outcomes</title><p>Ten of the included studies provided data on maternal mortality, comparing the prophylactic (n&#8197;=&#8197;778 patients) and control (n&#8197;=&#8197;709 patients) groups. The overall effect estimates favored the prophylactic group over the control group (OR&#8197;=&#8197;0.33; 95% CI = 0.10&#8211;1.13; <italic toggle="yes">P</italic>&#8197;=&#8197;.08), with no significant heterogeneity identified (<italic toggle="yes">P</italic>&#8197;=&#8197;.2) (Fig. <xref rid="F2" ref-type="fig">2</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Forest plot depicting maternal mortality comparison between prophylactic transfusion and control groups. CI = confidence interval, M-H = Mantel-Haenszel Test, df = Degrees of freedom.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39475-g002.jpg"/></fig><p>On the other hand, 13 studies reported the incidence of vaso-occlusive painful events, showing that the prophylactic group had lower rates than the control group (OR&#8197;=&#8197;0.31; 95% CI = 0.14&#8211;0.73; <italic toggle="yes">P</italic>&#8197;=&#8197;.007). However, significant heterogeneity was detected (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.00001; I<sup>2</sup>&#8197;=&#8197;89%) (Fig. <xref rid="F3" ref-type="fig">3</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Forest plot illustrating the comparison of vaso-occlusive pain events between the prophylactic transfusion and control groups. CI = confidence interval, M-H = Mantel-Haenszel Test, df = Degrees of freedom.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39475-g003.jpg"/></fig><p>Similarly, the prophylactic group exhibited fewer pulmonary complications than the control group (OR&#8197;=&#8197;0.21; 95% CI = 0.08&#8211;0.53; <italic toggle="yes">P</italic>&#8197;=&#8197;.001), although there was significant heterogeneity (<italic toggle="yes">P</italic>&#8197;&lt;&#8197;.01; I<sup>2</sup>&#8197;=&#8197;76%) (Fig. <xref rid="F4" ref-type="fig">4</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Forest plot illustrating the comparison of pulmonary complications between the prophylactic transfusion and control groups. CI = confidence interval, M-H = Mantel-Haenszel Test, df = Degrees of freedom.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39475-g004.jpg"/></fig><p>In contrast, the prophylactic group showed a significant advantage over the control group in terms of preeclampsia (OR&#8197;=&#8197;0.40; 95% CI = 0.19&#8211;0.82; <italic toggle="yes">P</italic>&#8197;=&#8197;.02) (Fig. <xref rid="F5" ref-type="fig">5</xref>).</p><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Forest plot depicting the comparison of preeclampsia between the prophylactic transfusion and control groups. CI = confidence interval, M-H = Mantel-Haenszel Test, df = Degrees of freedom.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39475-g005.jpg"/></fig></sec><sec><title>3.4.2. Fetal outcomes</title><p>Regarding fetal outcomes, 11 studies included in our analysis reported differences in perinatal mortality between the prophylactic (n&#8197;=&#8197;831 patients) and control (n&#8197;=&#8197;772 patients) groups. The overall effect estimates favored the prophylactic group over the control group (OR&#8197;=&#8197;0.35; 95% CI = 0.17&#8211;0.75; <italic toggle="yes">P</italic>&#8197;=&#8197;.03); however, there was moderate heterogeneity in the pooled effect estimate (<italic toggle="yes">P</italic>&#8197;=&#8197;.07; I<sup>2</sup>&#8197;=&#8197;41%) (Fig. <xref rid="F6" ref-type="fig">6</xref>).</p><fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><p>Forest plots illustrating the disparity in perinatal mortality between the prophylactic and control groups. CI = confidence interval, M-H = Mantel-Haenszel Test, df = Degrees of freedom.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39475-g006.jpg"/></fig><p>Similarly, 9 studies reported on the effect of prophylactic transfusion on the incidence of preterm birth, with the overall effect estimates favoring the prophylactic group over the control group (OR&#8197;=&#8197;0.67; 95% CI = 0.47&#8211;0.96; <italic toggle="yes">P</italic>&#8197;=&#8197;.02); no significant heterogeneity was identified (<italic toggle="yes">P</italic>&#8197;=&#8197;.13). In contrast, the overall effect estimate did not favor the prophylactic group over the control group in terms of the incidence of SGA newborns (OR&#8197;=&#8197;0.58; 95% CI = 0.55&#8211;1.32; <italic toggle="yes">P</italic>&#8197;=&#8197;.46).</p></sec></sec></sec><sec sec-type="discussion"><title>4. Discussion</title><p>The existing literature presents divergent findings regarding the effectiveness and safety of prophylactic transfusion in pregnant women with SCD. In this systematic review and meta-analysis, prophylactic blood transfusion demonstrated a statistically significant reduction in both maternal and perinatal mortality compared with on-demand transfusion. Additionally, the prophylactic transfusion group exhibited a significantly lower incidence of vaso-occlusive painful events, pulmonary complications, and preterm birth. However, there was a significant advantage observed for the prophylactic group concerning the incidence of preeclampsia and SGA newborns. It is important to note that there were statistically significant heterogeneities in most of the pooled effect estimates.</p><p>SCD is one of the most prevalent hereditary disorders, characterized by severe adverse events in its severe forms. It is well documented that pregnancy is a major risk factor for serious maternal complications in SCD patients, with recent studies indicating significantly elevated risks of maternal mortality, preeclampsia, and painful vaso-occlusive events in pregnant women with SCD.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup></p><p>However, there remains a lack of consensus regarding the most effective transfusion strategy for managing pregnancy-associated adverse events in patients with SCD. In our meta-analysis, we found that prophylactic blood transfusion led to a statistically significant reduction in maternal mortality, incidence of vaso-occlusive painful events, pulmonary complications, and reduction in preeclampsia compared with on-demand transfusion. This aligns with the findings of Malinowski et al,<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> who reported similar reductions in maternal mortality, vaso-occlusive pain episodes, pulmonary complications, pulmonary embolism, and pyelonephritis associated with prophylactic transfusion.</p><p>Likewise, a recent systematic review indicated a statistically significant reduction in maternal mortality and vaso-occlusive pain episodes following prophylactic blood transfusion.<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> However, it is important to note the contrasting results from the only available randomized controlled trial in the literature that reported no statistically significant improvements in maternal outcomes with prophylactic transfusion, except for the incidence of painful vaso-occlusive events.<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> The ability of this trial to detect significant results is questionable owing to its small sample size and high risk of bias.</p><p>Additionally, pregnancy has a notable impact on fetal outcomes in patients with SCD. Existing evidence indicates that pregnancy significantly increases the risk of perinatal mortality, preterm birth, and intrauterine growth restriction in this population.<sup>[<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref>]</sup> Our meta-analysis revealed that the prophylactic blood transfusion group had a significantly lower perinatal mortality rate and preterm birth incidence. However, there was no significant advantage observed for the prophylactic group in terms of the incidence of SGA newborns.</p><p>Consistent with our findings, Jackson et al<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> reported that the majority of available data indicated lower perinatal mortality rates in the group that received prophylactic blood transfusions. Malinowski et al<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> reported similar results regarding improved fetal outcomes associated with prophylactic transfusion.</p><p>The current systematic review and meta-analysis had several strengths. The review adhered to the recommendations outlined in the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement, ensuring a rigorous and transparent methodology. Furthermore, controlled studies were exclusively included to mitigate the risk of methodological bias.</p><p>However, it is important to acknowledge the limitations of this study. Significant inconsistencies were observed in the pooled effect estimates, likely because of wide variations in the characteristics of the study populations, designs, and transfusion protocols. Additionally, the methodological quality of the included studies ranged from low to moderate, which may have affected the overall quality of the evidence presented in this review.</p></sec><sec><title>5. Conclusion</title><p>In conclusion, the findings of the present meta-analysis suggest that prophylactic blood transfusion in pregnant women with SCD may lead to improved maternal and fetal outcomes. The prophylactic group showed lower rates of mortality, painful vaso-occlusive events, pulmonary complications, preeclampsia, perinatal mortality, and preterm births. However, it is crucial to note that there were significant variations in the methodology and transfusion protocols across the included studies, which resulted in considerable statistical heterogeneity in the pooled effect estimates.</p><p>Current evidence appears to be insufficient to definitively support the clinical decision to routinely use prophylactic transfusion over symptomatic transfusion for SCD during pregnancy. Further well-designed studies are warranted to provide more robust evidence.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> May AlMoshary.</p><p><bold>Data curation:</bold> May AlMoshary, Maria Arabdin.</p><p><bold>Formal analysis:</bold> May AlMoshary, Maria Arabdin.</p><p><bold>Funding acquisition:</bold> May AlMoshary.</p><p><bold>Investigation:</bold> May AlMoshary.</p><p><bold>Methodology:</bold> May AlMoshary.</p><p><bold>Project administration:</bold> Maria Arabdin.</p><p><bold>Resources:</bold> Maria Arabdin.</p><p><bold>Software:</bold> Maria Arabdin.</p><p><bold>Supervision:</bold> Maria Arabdin.</p><p><bold>Validation:</bold> Maria Arabdin.</p><p><bold>Visualization:</bold> Maria Arabdin.</p><p><bold>Writing &#8211; original draft:</bold> Maria Arabdin.</p><p><bold>Writing &#8211; review &amp; editing:</bold> Maria Arabdin.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" id="s1" content-type="document" xlink:href="medi-103-e39475-s001.docx" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>HbS</term><def><p>hemoglobin</p></def></def-item><def-item><term>OR</term><def><p>odds ratio</p></def></def-item><def-item><term>SCD</term><def><p>sickle cell disease</p></def></def-item><def-item><term>SGA</term><def><p>small for gestational age</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.</p></fn><fn fn-type="other"><p>Ethical approval is typically not required for systematic reviews and meta-analyses that only use data from previously published studies. This is because these types of research do not involve direct contact with human subjects or the collection of new data from human participants. Instead, they analyze and synthesize data that have already been published in the scientific literature.</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>All data generated or analyzed during this study are included in this published article (and its supplementary information files).</p></fn><fn fn-type="supplementary-material"><p>Supplemental Digital Content is available for this article.</p></fn><fn fn-type="other"><p>How to cite this article: AlMoshary M, Arabdin M. The role of prophylactic transfusion on the maternal and fetal outcomes in pregnant women with sickle cell disease: A systematic review and meta-analysis. Medicine 2024;103:36(e39475).</p></fn></fn-group><ref-list id="r2"><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rees</surname><given-names>DC</given-names></name><name name-style="western"><surname>Williams</surname><given-names>TN</given-names></name><name name-style="western"><surname>Gladwin</surname><given-names>MT</given-names></name></person-group>. <article-title>Sickle-cell disease.</article-title><source>Lancet</source>. <year>2010</year>;<volume>376</volume>:<fpage>2018</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">21131035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(10)61029-X</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ware</surname><given-names>RE</given-names></name><name name-style="western"><surname>de Montalembert</surname><given-names>M</given-names></name><name name-style="western"><surname>Tshilolo</surname><given-names>L</given-names></name><name name-style="western"><surname>Abboud</surname><given-names>MR</given-names></name></person-group>. <article-title>Sickle cell disease.</article-title><source>Lancet</source>. <year>2017</year>;<volume>390</volume>:<fpage>311</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">28159390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)30193-9</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oteng-Ntim</surname><given-names>E</given-names></name><name name-style="western"><surname>Meeks</surname><given-names>D</given-names></name><name name-style="western"><surname>Seed</surname><given-names>PT</given-names></name><etal/></person-group>. <article-title>Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis.</article-title><source>Blood</source>. <year>2015</year>;<volume>125</volume>:<fpage>3316</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">25800049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2014-11-607317</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malowany</surname><given-names>JI</given-names></name><name name-style="western"><surname>Butany</surname><given-names>J</given-names></name></person-group>. <article-title>Pathology of sickle cell disease.</article-title><source>Semin Diagn Pathol</source>. <year>2012</year>;<volume>29</volume>:<fpage>49</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">22372205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.semdp.2011.07.005</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afolabi</surname><given-names>BB</given-names></name><name name-style="western"><surname>Iwuala</surname><given-names>NC</given-names></name><name name-style="western"><surname>Iwuala</surname><given-names>IC</given-names></name><name name-style="western"><surname>Ogedengbe</surname><given-names>OK</given-names></name></person-group>. <article-title>Morbidity and mortality in sickle cell pregnancies in Lagos, Nigeria: a case control study.</article-title><source>J Obstet Gynaecol</source>. <year>2009</year>;<volume>29</volume>:<fpage>104</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">19274540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01443610802667112</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>CK</given-names></name><name name-style="western"><surname>Stasiowska</surname><given-names>E</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>A</given-names></name><name name-style="western"><surname>Awogbade</surname><given-names>M</given-names></name><name name-style="western"><surname>Davies</surname><given-names>A</given-names></name></person-group>. <article-title>Outcome of pregnancy in sickle cell disease patients attending a combined obstetric and haematology clinic.</article-title><source>J Obstet Gynaecol</source>. <year>2009</year>;<volume>29</volume>:<fpage>512</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">19697199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01443610903003175</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>DT</given-names></name><name name-style="western"><surname>Molokie</surname><given-names>R</given-names></name></person-group>. <article-title>Sickle cell disease in pregnancy.</article-title><source>Obstet Gynecol Clin North Am</source>. <year>2010</year>;<volume>37</volume>:<fpage>223</fpage>&#8211;<lpage>37</lpage>.<pub-id pub-id-type="pmid">20685550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ogc.2010.02.015</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villers</surname><given-names>MS</given-names></name><name name-style="western"><surname>Jamison</surname><given-names>MG</given-names></name><name name-style="western"><surname>De Castro</surname><given-names>LM</given-names></name><name name-style="western"><surname>James</surname><given-names>AH</given-names></name></person-group>. <article-title>Morbidity associated with sickle cell disease in pregnancy.</article-title><source>Am J Obstet Gynecol</source>. <year>2008</year>;<volume>199</volume>:<fpage>125.e1</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2008.04.016</pub-id><pub-id pub-id-type="pmid">18533123</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townsley</surname><given-names>DM</given-names></name></person-group>. <article-title>Hematologic complications of pregnancy.</article-title><source>Semin Hematol</source>. <year>2013</year>;<volume>50</volume>:<fpage>222</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">23953339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.seminhematol.2013.06.004</pub-id><pub-id pub-id-type="pmcid">PMC3748382</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Tuck</surname><given-names>SM</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>TC</given-names></name></person-group>. <article-title>Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome.</article-title><source>Br J Obstet Gynaecol</source>. <year>1995</year>;<volume>102</volume>:<fpage>947</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">8652484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-0528.1995.tb10900.x</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ware</surname><given-names>RE</given-names></name><name name-style="western"><surname>Helms</surname><given-names>RW</given-names></name><name name-style="western"><surname>Investigators</surname><given-names>SW</given-names></name></person-group>. <article-title>Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).</article-title><source>Blood</source>. <year>2012</year>;<volume>119</volume>:<fpage>3925</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">22318199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2011-11-392340</pub-id><pub-id pub-id-type="pmcid">PMC3350359</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>J</given-names></name><name name-style="western"><surname>Malfroy</surname><given-names>M</given-names></name><name name-style="western"><surname>Llewelyn</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.</article-title><source>Lancet</source>. <year>2013</year>;<volume>381</volume>:<fpage>930</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23352054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(12)61726-7</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahomed</surname><given-names>K</given-names></name></person-group>. <article-title>Prophylactic versus selective blood transfusion for sickle cell anaemia during pregnancy.</article-title><source>Cochrane Database Syst Rev</source>. <year>2000</year>;<volume>2</volume>:<fpage>CD000040</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD000040</pub-id><pub-id pub-id-type="pmid">10796098</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilli</surname><given-names>SC</given-names></name><name name-style="western"><surname>De Paula</surname><given-names>EV</given-names></name><name name-style="western"><surname>Biscaro</surname><given-names>FP</given-names></name><name name-style="western"><surname>Marques</surname><given-names>JF</given-names></name><name name-style="western"><surname>Costa</surname><given-names>FF</given-names></name><name name-style="western"><surname>Saad</surname><given-names>ST</given-names></name></person-group>. <article-title>Third-trimester erythrocytapheresis in pregnant patients with sickle cell disease.</article-title><source>Int J Gynaecol Obstet</source>. <year>2007</year>;<volume>96</volume>:<fpage>8</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">17188271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijgo.2006.09.017</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asma</surname><given-names>S</given-names></name><name name-style="western"><surname>Kozanoglu</surname><given-names>I</given-names></name><name name-style="western"><surname>Tarim</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Prophylactic red blood cell exchange may be beneficial in the management of sickle cell disease in pregnancy.</article-title><source>Transfusion</source>. <year>2015</year>;<volume>55</volume>:<fpage>36</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">25070465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/trf.12780</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malinowski</surname><given-names>AK</given-names></name><name name-style="western"><surname>Shehata</surname><given-names>N</given-names></name><name name-style="western"><surname>D&#8217;Souza</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis.</article-title><source>Blood</source>. <year>2015</year>;<volume>126</volume>:<fpage>2424</fpage>&#8211;<lpage>35; quiz 2437</lpage>.<pub-id pub-id-type="pmid">26302758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2015-06-649319</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutton</surname><given-names>B</given-names></name><name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name><name name-style="western"><surname>Caldwell</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.</article-title><source>Ann Intern Med</source>. <year>2015</year>;<volume>162</volume>:<fpage>777</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">26030634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M14-2385</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stroup</surname><given-names>DF</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>JA</given-names></name><name name-style="western"><surname>Morton</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group.</article-title><source>JAMA</source>. <year>2000</year>;<volume>283</volume>:<fpage>2008</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">10789670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.283.15.2008</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>GA</given-names></name><name name-style="western"><surname>Shea</surname><given-names>B</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.</article-title><year>2000</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cmr.cochrane.org/?CRGReportID=2972" ext-link-type="uri">https://cmr.cochrane.org/?CRGReportID=2972</ext-link>.</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benites</surname><given-names>BD</given-names></name><name name-style="western"><surname>Benevides</surname><given-names>TC</given-names></name><name name-style="western"><surname>Valente</surname><given-names>IS</given-names></name><name name-style="western"><surname>Marques</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Gilli</surname><given-names>SC</given-names></name><name name-style="western"><surname>Saad</surname><given-names>ST</given-names></name></person-group>. <article-title>The effects of exchange transfusion for prevention of complications during pregnancy of sickle hemoglobin C disease patients.</article-title><source>Transfusion</source>. <year>2016</year>;<volume>56</volume>:<fpage>119</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">26337929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/trf.13280</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>JM</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Horger</surname><given-names>EO</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Key</surname><given-names>TC</given-names></name><name name-style="western"><surname>Walker</surname><given-names>EM</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Management of sickle hemoglobinopathies in pregnant patients.</article-title><source>Am J Obstet Gynecol</source>. <year>1981</year>;<volume>141</volume>:<fpage>237</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">7282804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9378(16)32625-4</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Shafei</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kaur Dhaliwal</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaur Sandhu</surname><given-names>A</given-names></name><name name-style="western"><surname>Rashid Al-Sharqi</surname><given-names>M</given-names></name></person-group>. <article-title>Indications for blood transfusion in pregnancy with sickle cell disease.</article-title><source>Aust NZJ Obstet Gynaecol</source>. <year>1995</year>;<volume>35</volume>:<fpage>405</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1479-828x.1995.tb02153.x</pub-id><pub-id pub-id-type="pmid">8717565</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koshy</surname><given-names>M</given-names></name><name name-style="western"><surname>Chisum</surname><given-names>D</given-names></name><name name-style="western"><surname>Burd</surname><given-names>L</given-names></name><name name-style="western"><surname>Orlina</surname><given-names>A</given-names></name><name name-style="western"><surname>How</surname><given-names>H</given-names></name></person-group>. <article-title>Management of sickle cell anemia and pregnancy.</article-title><source>J Clin Apher</source>. <year>1991</year>;<volume>6</volume>:<fpage>230</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">1816245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jca.2920060412</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrison</surname><given-names>JC</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>FS</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>RC</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>WE</given-names></name><name name-style="western"><surname>Hess</surname><given-names>LW</given-names></name><name name-style="western"><surname>Wiser</surname><given-names>WL</given-names></name></person-group>. <article-title>Use of continuous flow erythrocytapheresis in pregnant patients with sickle cell disease.</article-title><source>J Clin Apher</source>. <year>1991</year>;<volume>6</volume>:<fpage>224</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">1816244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jca.2920060411</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>FG</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>JA</given-names></name><name name-style="western"><surname>Mason</surname><given-names>R</given-names></name></person-group>. <article-title>Pregnancy and sickle cell hemoglobinopathies: results with and without prophylactic transfusions.</article-title><source>Obstet Gynecol</source>. <year>1983</year>;<volume>62</volume>:<fpage>419</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">6888818</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuck</surname><given-names>SM</given-names></name><name name-style="western"><surname>James</surname><given-names>CE</given-names></name><name name-style="western"><surname>Brewster</surname><given-names>EM</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>TC</given-names></name><name name-style="western"><surname>Studd</surname><given-names>JW</given-names></name></person-group>. <article-title>Prophylactic blood transfusion in maternal sickle cell syndromes.</article-title><source>Br J Obstet Gynaecol</source>. <year>1987</year>;<volume>94</volume>:<fpage>121</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">3828251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-0528.1987.tb02337.x</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeil</surname><given-names>JA</given-names></name><name name-style="western"><surname>Labopin</surname><given-names>M</given-names></name><name name-style="western"><surname>Stanislas</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: a retrospective survey by the international sickle cell disease observatory.</article-title><source>Am J Hematol</source>. <year>2018</year>;<volume>93</volume>:<fpage>794</fpage>&#8211;<lpage>802</lpage>.<pub-id pub-id-type="pmid">29603363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajh.25097</pub-id><pub-id pub-id-type="pmcid">PMC6001537</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yilmaz Baran</surname><given-names>S</given-names></name><name name-style="western"><surname>Kozanoglu</surname><given-names>I</given-names></name><name name-style="western"><surname>Korur</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Role of prophylactic and therapeutic red blood cell exchange in pregnancy with sickle cell disease: maternal and perinatal outcomes.</article-title><source>J Clin Apher</source>. <year>2021</year>;<volume>36</volume>:<fpage>283</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">32797735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jca.21819</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngo</surname><given-names>C</given-names></name><name name-style="western"><surname>Kayem</surname><given-names>G</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Pregnancy in sickle cell disease: maternal and fetal outcomes in a population receiving prophylactic partial exchange transfusions.</article-title><source>Eur J Obstet Gynecol Reprod Biol</source>. <year>2010</year>;<volume>152</volume>:<fpage>138</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">20846778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejogrb.2010.05.022</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sousa</surname><given-names>VT</given-names></name><name name-style="western"><surname>Ballas</surname><given-names>SK</given-names></name><name name-style="western"><surname>Leite</surname><given-names>JM</given-names></name><name name-style="western"><surname>Olivato</surname><given-names>MCA</given-names></name><name name-style="western"><surname>Cancado</surname><given-names>RD</given-names></name></person-group>. <article-title>Maternal and perinatal outcomes in pregnant women with sickle cell disease: an update.</article-title><source>Hematol Transfus Cell Ther</source>. <year>2022</year>;<volume>44</volume>:<fpage>369</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">33716021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.htct.2020.12.009</pub-id><pub-id pub-id-type="pmcid">PMC9477754</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrison</surname><given-names>JC</given-names></name><name name-style="western"><surname>Whybrew</surname><given-names>WD</given-names></name><name name-style="western"><surname>Bucovaz</surname><given-names>ET</given-names></name></person-group>. <article-title>Use of partial exchange transfusion preoperatively in patients with sickle cell hemoglobinopathies.</article-title><source>Am J Obstet Gynecol</source>. <year>1978</year>;<volume>132</volume>:<fpage>59</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">696786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9378(78)90799-8</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>B</given-names></name><name name-style="western"><surname>Fasano</surname><given-names>R</given-names></name><name name-style="western"><surname>Roback</surname><given-names>J</given-names></name></person-group>. <article-title>Current evidence for the use of prophylactic transfusion to treat sickle cell disease during pregnancy.</article-title><source>Transfus Med Rev</source>. <year>2018</year>;<volume>32</volume>:<fpage>220</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">30029813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tmrv.2018.06.001</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koshy</surname><given-names>M</given-names></name><name name-style="western"><surname>Burd</surname><given-names>L</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>D</given-names></name><name name-style="western"><surname>Moawad</surname><given-names>A</given-names></name><name name-style="western"><surname>Baron</surname><given-names>J</given-names></name></person-group>. <article-title>Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study.</article-title><source>N Engl J Med</source>. <year>1988</year>;<volume>319</volume>:<fpage>1447</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">3054555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM198812013192204</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimy</surname><given-names>MC</given-names></name><name name-style="western"><surname>Gangbo</surname><given-names>A</given-names></name><name name-style="western"><surname>Adjou</surname><given-names>R</given-names></name><name name-style="western"><surname>Deguenon</surname><given-names>C</given-names></name><name name-style="western"><surname>Goussanou</surname><given-names>S</given-names></name><name name-style="western"><surname>Alihonou</surname><given-names>E</given-names></name></person-group>. <article-title>Effect of active prenatal management on pregnancy outcome in sickle cell disease in an African setting.</article-title><source>Blood</source>. <year>2000</year>;<volume>96</volume>:<fpage>1685</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10961864</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>PM</given-names></name><name name-style="western"><surname>Wilburn</surname><given-names>W</given-names></name><name name-style="western"><surname>Raynor</surname><given-names>BD</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>D</given-names></name></person-group>. <article-title>Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia.</article-title><source>Am J Obstet Gynecol</source>. <year>2001</year>;<volume>184</volume>:<fpage>1127</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">11349177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mob.2001.115477</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>